wolf creek casino
From 1h ago 20.42 CET 'Protestival' to start in Newcastle harbour Climate activists will take to the water today to protest against fossil fuels at the world's biggest coal port despite government efforts to crack down on the action, AAP reports. The multi-day "protestival" will occupy parts of Newcastle harbour and foreshore with a flotilla, live music and other events revolving around protest and climate. Former federal minister and Midnight Oil frontman Peter Garrett will join the live music lineup that will be audible both on land and from the water. It follows a successful last-minute legal challenge by organisers, Rising Tide, to overturn a planned "marine exclusion zone" by the government that would have prevented the protesters from entering the water. As a result, the group said protesters could peacefully enter the water off Horseshoe Beach, near the mouth of the harbour, to conduct a flotilla without impeding the nearby shipping channel. NSW police have repeatedly flagged concerns with the safety of the event, citing a similar action in 2023 that resulted in the arrests of nine people who refused to exit the water at an agreed time. Rising Tide said it was calling for an end to new coal and gas approvals, and the imposition of a 78% tax on coal and gas exports to help fund the energy transition. Read more: NSW government bid to prevent Rising Tide protest in Newcastle harbour invalid, court finds Read more Share Updated at 21.06 CET 6m ago 21.48 CET Kylea Tink was asked a question about changes to the Future Fund, and spoke about the amount of legislation the government is trying to pass, with just four sitting days left this year: We are in the final two sitting weeks of this year and I can pretty much guarantee from this point on it will either be about the government rushing to finish its homework, so stuff we should have seen months ago being forced through, while on the other hand it will be all about cheap political points-scoring. Tink said she... Emily Wind , Paul Karp , Caitlin Cassidy , Martin FarrerTrump reaches required agreement with Biden White House to begin formal transition handoff, but foregoes other support
Texans foiled by mistake after mistake in 32-27 loss to TitansJimmy Carter: Many evolutions for a centenarian ‘citizen of the world’
Rudy Giuliani draws rebuke for a courtroom outburst accusing judge in assets case of being unfair
Sceptic Skip, the self-styled Cromer seer, is back to pass on the only authentic home-grown crop of prognostications untainted by prejudice or pressures dressed up as promises. Norfolk’s answer to Cassandra, Nostradamus and Mother Shipton presents his exclusive predictions for the county in 2025, banking again on the old adage that people don’t always believe everything they read – but repeat it to be just on the safe side. With no grants from the Arts Council, Brussels or the Poppyland Soothsayers’ Association, he admits it has been tougher than usual to find scope and inspiration for confident forecasting “ in these breathtakingly ominous times”. January – Television viewers in Norfolk and north Suffolk ask for the old signal to be turned back on because they claim programmes have deteriorated so much since switch to digital transmission. Spokesperson Anna Log says one critic suggested television was called a medium “because so little of it is rare or well done.” Norfolk “parish harmony” programme launched as Egmere is twinned with Baconsthorpe. February -More BBC cuts begin to bite at local level. Radio Norfolk introduces new service for Norwich City’s away fixtures whereby match referees are wired up to provide unbiased running commentaries. Listeners complain about reception affected by strange whistling noises. . Appleton twinned with Syderstone as part of “joint core strategy.” March - Signs of improvement on the Norwich-London railway service following celebrity endorsement by Alan Partridge and Michael Portillo’ ‘ All train drivers now assured of a seat each way. Manningtree halt closed and declared a World Heritage Site. Bale twined with Wheatacre. April – Alarming indications of more serious erosion along the north Norfolk coast. Aylsham inshore lifeboat launched twice. North Walsham lighthouse goes digital. Reepham coastguards seek new recruits. Sidestrand offered a bypass in return for permission to build 500 clifftop retirement homes and an elastic stocking factory. Herringby twinned with Cranworth. May - Housing market picking up. First-time buyers spotted in Burnham Deepdale and North Creake. Survey by Chelsea (Cheaper Homes Encouraged by Local Society of Estate Agents) hints that rural deprivation in some parts of Norfolk means being unable to buy William Morris wallpaper at the village shop. Rushall twinned with Sloley – eventually. June – “Been there. Done that. Can’t remember.” – slogan spotted on senior citizen’s T-shirt in Cromer. Bumper tourist season forecast. Elephant Experience theme park at West Runton voted the area’s best new attraction, complete with trumpeting bays billed as “alternative hunting where you form your own tusk force.” Swannington twinned with Cobholm. July – Singing Postman Academy opened in Burnham Market in honour of cultural local icon and to encourage closer ties between well-heeled visitors and settlers with village natives still claiming to “tork proper”. Four giant solar farms shut down in Norfolk due to lack of sunshine. Dickleburgh refuses to twin with Whittington as it’s too far away. August- Mini-Olympics for Norfolk parish councillors off to a lively start. Briston, Hickling and Knapton disqualified from tug-of-war for pushing and also experience problems in handing over batons in relay races. Even so, they all win their 4x400m heats in one hour and 26 minutes of the last emergency meeting. Wood Rising lift tossing-the-caber crown. Foxley twinned with Wolferton. September – Pedlar of Swaffham surprise winner of the East Anglian leg of Tour of Britain Cycle Race after taking advantage of new park-and-ride service at Little Cressingham. Temperatures dip to record lows at end of the month. Man falls out of bed in Great Snoring and cracks his pyjamas’ Babingley twinned with Brooke. October More BBC cuts and Radio Norfolk forced to repeat old favourites first aired on the national network and now given a more homely flavour. Programmes include Round the Horning, Much Binding in the Marsham, Dick Barton Turf, Have a Hoe, Brooke at Bedtime and Brain of Fritton. Burston twinned with Riddlesworth. November - Confusion reigns on Norfolk County Council. Six Labour members, five Liberal Democrats and a dozen Conservatives defect to the Greens while 23 others resign altogether because there’s nowhere else left for them to go. Norfolk Independence Party takes caretaker control under the banner; “Why not dew diffrunt and stay the same?” Upwell twinned with Downham. December - Christmas lights cut back radically in most Norfolk towns to reflect an increasingly bleak economic picture. King’s Lynn a shining exception. Glow and heat from a new installation nearby brings comfort and joy to a grand outdoor carol concert on the Tuesday Market Place. Bodham twinned with Gomorrah.
BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND ANNOUNCES DEBT SETTLEMENT AGREEMENTVANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “ Company ”, “ Rakovina ”, or “ Rakovina Therapeutics ”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the closing of a $3.0 million private placement. The private placement consists of 50,000,000 units (the “ Units ”) at a price of $0.06 per Unit. Each Unit consists of one common share of the Company (each, a “ Common Share ”) and one Common Share purchase warrant (each, a “ Warrant ”). Each Warrant entitles the holder thereof to subscribe for and purchase one Common Share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share. Rakovina retains the right to accelerate the Warrant exercise period if, upon written notice to the holder, the 20-day volume-weighted average price of its Common Shares exceeds $0.30. In connection with the Private Placement, the Company paid cash finder’s fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., Research Capital Corporation, Hampton Securities Limited, Ewing Morris & Co. Investment Partners Ltd. and Leede Financial Inc. (each a “ Finder ”, and collectively, the “ Finders ”) in the aggregate amount of $180,841 and issued a total of 3,021,872 non-transferable finder’s warrants (each, a “ Finder’s Warrant ’) to the Finders, in accordance with the policies of the TSX Venture Exchange (the “ TSXV ”). Each Finder’s Warrant entitles the holder thereof to subscribe for and purchase one Common share of the Company for a period of 24 months from the date of issue at a price of $0.10 per Common Share, subject to acceleration on the same terms as the Warrants issued in connection with the private placement. The private placement is subject to the final acceptance of the TSXV and all securities issuable in connection with the private placement are subject to a hold period of four months plus one day from the date of issuance, in accordance with applicable securities laws. The proceeds of the private placement will be used to accelerate both discovery and development of the Company’s proprietary drug candidates, shortlisted from the Deep Docking and Variational AI platforms. “This overwhelming response from our investors underscores the strength of our science, the extraordinary talent and dedication of our team and the transformative potential of our therapies,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “We are deeply grateful for the trust placed in us and remain resolute in our mission to utilize leading AI technologies to develop innovative solutions for cancer care.” The Company extends its heartfelt thanks to its investors, partners, and team for their unwavering support as Rakovina continues its work to bring new hope to patients and families affected by cancer. Rakovina is pleased to announce its engagement of Fairfax Partners Inc. as its Investor Relations (IR) partner. With extensive expertise in investor engagement strategies, Fairfax will implement a comprehensive six-month IR program designed to enhance Rakovina’s market presence and expand its investor base. The program, which includes an option to renew for an additional six months, focuses on complementing traditional IR efforts with targeted online marketing campaigns, activation of a robust social media influencer network, and collaboration with external consultants and global wealth management channels. These initiatives will support Rakovina’s strategic plan for 2025 by institutionalizing its investor base and strengthening its distribution capabilities. Under the agreement, Fairfax will receive a monthly fee of $5,000 plus GST, a one-time setup fee of $15,000 plus GST, and a marketing budget of $120,000 plus GST, disbursed as follows: $80,000 upon signing and $40,000 two months later. Services provided by Fairfax include inbound and outbound phone communications, website and social media management, marketing material preparation, news release support, and roadshow assistance, ensuring Rakovina’s IR efforts align with market expectations. Fairfax Partners Inc., located at 306-1238 Seymour Street, Vancouver, BC, confirms that neither its directors nor officers hold any securities of Rakovina. For inquiries, please contact connect@fairfaxpartners.com. “We are thrilled to partner with the seasoned team at Fairfax Partners to expand our investor base and increase awareness of Rakovina Therapeutics’ vision. Fairfax’s creative and forward-thinking approach to investor relations will be a critical asset as we enter a pivotal year. By harnessing their extensive network and digital expertise, we aim to significantly enhance our market presence and deliver lasting value to our shareholders,” said Mr. Bacha. About Rakovina Therapeutics Inc. Rakovina Therapeutics Inc. is dedicated to developing innovative cancer therapies targeting the DNA-damage response. The company has established a development pipeline of novel DNA-damage response inhibitors by leveraging Artificial Intelligence (AI) to accelerate the identification and optimization of drug candidates. Rakovina Therapeutics aims to advance one or more of these candidates into human clinical trials in collaboration with pharmaceutical partners and secure marketing approvals from Health Canada, the U.S. Food and Drug Administration, and other international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com . The TSXV has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Forward-Looking Statements: This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the terms of the private placement, the closing of the private placement, the receipt of final TSXV approval, the proposed business plan of the Company; the Company’s commitment to advancing new cancer therapies; the ability of the Company to extract value from its AI collaborations; the Company’s ability to execute on its business plans while maintaining high standards of research; the ability of Pharma Inventor Inc. to accurately provide medicinal chemistry support; the projected timeline and effectiveness of the Company’s strategy to utilize the Deep Docking AI platform; and the Company’s ability to generate shareholder value. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at www.sedar.com. For Further Information Contact: David Hyman, Chief Financial Officer info@rakovinatherapeutics.com Invest Relations &Media Michelle Seltenrich ir@rakovinatherapeutics.com 778-773-5432
Six things we learned on the campaign trail today
- Previous: wolf casino slots
- Next: wolf gold casino game
